Renaissance Technologies’s Sagimet Biosciences SGMT Stock Holding History

Renaissance Technologies’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.27M	Buy	625,469 +282,969	+83%	+$1.58M	0.01%	1616
2025 Q4	$2.03M	Buy	342,500 +181,100	+112%	+$1.3M	﹤0.01%	1858
2025 Q3	$1.11M	Buy	161,400 +130,500	+422%	+$1.06M	﹤0.01%	2428
2025 Q2	$235K	Buy	+30,900	New	+$130K	﹤0.01%	3125
2025 Q1	–	Sell	-10,800	Closed	-$48.6K	–	3798
2024 Q4	$48.6K	Sell	10,800 -220,300	-95%	-$1.12M	﹤0.01%	3395
2024 Q3	$640K	Sell	231,100 -11,300	-5%	-$34.8K	﹤0.01%	2671
2024 Q2	$829K	Sell	242,400 -177,000	-42%	-$812K	﹤0.01%	2426
2024 Q1	$2.27M	Buy	419,400 +396,400	+1,723%	+$2.85M	﹤0.01%	1948
2023 Q4	$125K	Buy	+23,000	New	+$109K	﹤0.01%	3249

Other funds holding SGMT

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Renaissance Technologies's SGMT Position: Q1 2026 in Review

Renaissance Technologies increased its Sagimet Biosciences (SGMT) stake by 83% in Q1 2026, buying an estimated $1.58M and bringing the position to 625,469 shares worth $3.27M. The position accounts for 0.01% of the portfolio, ranked #1616.

Renaissance Technologies first reported a position in SGMT in Q4 2023 and has held it in 9 quarters since. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

Renaissance Technologies held 625,469 shares of Sagimet Biosciences worth $3.27M as of Q1 2026.
Renaissance Technologies bought 282,969 Sagimet Biosciences shares in Q1 2026, an estimated $1.58M.
Sagimet Biosciences made up 0.01% of Renaissance Technologies's portfolio in Q1 2026, its #1616 holding.
Renaissance Technologies first reported a position in Sagimet Biosciences in Q4 2023 and has held it in 9 quarters since.
88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.